Conclusion: In the last years we have observed an encouraging increase of involved Countries, with a greater number of patients coming from geographic area poorly represented in the first epidemiologic study of Toplak et al. Eurofever data analysis has confirmed an improvement of diagnostic ability during the last years, with a significant reduction of mean diagnostic delay. Longterm studies will help understand the efficacy and safety of different treatments used in these rare conditions.

Disclosure of Interests: Martina Finetti: None declared, Ilaria Guelli: None declared. Joost Frenkel: None declared, Seza Özen Consultant for: Seza Özen is receiving consultancy fees from Novartis, Speakers bureau; Roche, Helen J. Lachmann Grant/research support from: SOBI, Novartis, Consultant for: Novartis, Takeda, Speakers bureau: SOBI, Novartis, Fabrizio De Benedetti Grant/research support from: Grant/ research support to Istituto Gaslini from GlaxoSmithKline immune-inflammation; unrestricted grant to study Blau syndrome; Roche: unrestricted research grant; Pfizer: grant for psychological care of patients with JIA, Grant/research support from: GSK, Roche, Pfizer, Paul Brogan Grant/research support from: SOBI, Novartis, Roche, Novimmune, Chemocentryx, Consultant for: Roche, SOBI, Speakers bureau: SOBI, Roche, Novartis, UCB, Hermann Girschick: None declared, Benedicte Neven: None declared, Alberto Martini Consultant for: I do not have any conflict of interest to declare since starting from 1 March 2016 I became the Scientific Director of the G. Gaslini Hospital; therefore, my role does not allow me to render private consultancies resulting in personal income. I perform consultancy activities on behalf of the Gaslini Institute for the companies listed below:

AbbVie, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, EMD Serono, Jansen, Novartis, Pfizer, R-Pharm.

The money received for these activities are directly transferred to the Gaslini Institute’s bank account. Before March 2016, I was the head of the Pediatric Rheumatology Department at the G. Gaslini Hospital, where the PRINTO Coordinating Centre is located. For the coordination activity of the PRINTO network, the Gaslini Hospital received contributions from the industries listed in this section. This money has been reinvested for the research activities of the hospital in fully independent manners without any commitment with third parties,... Niccolò Rupert Grant/research support from: The Gaslini Hospital, where NR works as full-time public employee, has received contributions (> 10.000 USD each) from the following industries in the last 3 years: BMS, Eli-Lilly, GlaxoSmithKline, F Hoffmann-La Roche, Janssen, Novartis, Pfizer, Sobi. This funding has been reinvested for the research activities of the hospital in a fully independent manner, without any commitment with third parties,... Consultant for: Received honoraria for consultancies or speaker bureaus (< 10.000 USD each) from the following pharmaceutical companies in the past 3 years: Ablynx, AbbVie, AstraZeneca-Medinmed, Biogen, Boehringer, Bristol-Myers Squibb, Eli-Lilly, EMD Serono, GlaxoSmithKline, Hoffmann-La Roche, Janssen, Merck, Novartis, Pfizer, R-Pharma, SanofiServier, Sobi, and Takeda. Speakers bureau: Received honoraria for consultancies or speaker bureaus (< 10.000 USD each) from the following pharmaceutical companies in the past 3 years: Ablynx, AbbVie, AstraZeneca-Medinmed, Biogen, Boehringer, Bristol-Myers Squibb, Eli-Lilly, EMD Serono, GlaxoSmithKline, Hoffmann-La Roche, Janssen, Merck, Novartis, Pfizer, R-Pharma, SanofiServier, Sobi, and Takeda.

References:

Acknowledgement: The National Paediatric Rheumatological Database has been funded by the German Children Arthritis Foundation (Deutsche Kinder-RheumaBildung), AbbVie, Pfizer and Chugai.

Disclosure of Interests: Florian Miltz: None declared, Jens Klotzsche: None declared, Martina Niewerth: None declared, Nils Geisemeyer: None declared, Jana Hörmstarr: None declared, Gerd Ganser: None declared, Ivan Foeldvari: Angelika Thoni: Rainer Berendes: Markus Hufnagel: Toni Hospach: Kirsten Minden: German Rheumatism Research Centre, Epidemiology, Berlin, Germany; St. Josef-Stift Hospital, Clinic of Pediatric Rheumatology, Sendenhorst, Germany; Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany; Medical School Hannover, Department of Pediatric Rheumatology, Allergology and Neonatology, Hannover, Germany; St. Marien’s Children’s Hospital Landshut, Department of Pediatric Rheumatology, Landshut, Germany; University Hospital Freiburg, Department of Pediatrics, Freiburg, Germany; Olga Hospital Stuttgart, Department of Pediatrics, Stuttgart, Germany; University Medicine Charité Berlin, Germany

Background: Patients with juvenile idiopathic arthritis (JIA) may have a different body composition associated with reduced muscle mass and increased fat mass [1]. They display decreased physical fitness, perform less strenuous physical activities, and spend more time sleeping than do healthy children, and physical activity is associated with deconditioning and functional deterioration, favoring an inactive lifestyle. The risk of overweight might be further increased by the glucocorticoid treatment.

Objectives: Since obesity can increase inflammatory processes, cause early atherosclerotic changes and promote metabolic disorders, the objectives were a) to determine the prevalence of overweight and obesity in children and adolescents with JIA, and b) to examine the association between overweight and health-related parameters in this population.

Methods: A cross-sectional analysis of physicians’ recorded body weights and heights of patients with JIA enrolled in the NPRD in the year 2016 was performed. Overweight was defined as BMI >80th sex- and age-specific percentile and obesity as BMI >90th percentile. For comparison with data from the general German population [2], patients aged 3 to 17 years were considered. A linear regression model was used to explore the association between overweight and both clinical and self-reported outcomes.

Results: In total, data from 6,860 children and adolescents with JIA (age 11.5 ± 4 years, disease duration 4.6 ± 3.6 years, 67% girls, 39% persistent oligoarthritis) were analyzed. Overweight was found in 14% (including 6% obesity) of JIA cases. Comparative data from the German general population report an overweight prevalence of 15% (including 6% obesity). In contrast to the general population, overweight rates in JIA differed between girls and boys (girls 14% vs. boys 16%, p<0.05). Patients with psoriatic arthritis (20%) and systemic JIA (18%) showed the highest overweight rates. In multivariate analyses, age (OR 1.04; 95%CI: 1.01-1.09), male sex (OR 1.21; 95%CI: 1.01-1.44), functional limitations (OR 1.29; 95%CI: 1.04-1.59), as well as therapy with biological DMARDs (OR 1.48; 95%CI: 1.22-1.80) and systemic glucocorticoids (OR 1.40; 95%CI: 1.14-1.71) were significantly associated with overweight.

Conclusion: The prevalence of overweight and obesity in young patients with JIA is similar to that of children and adolescents in the general population. The overweight rate increases with age and is strongly associated with functional restrictions and treatment with glucocorticoids. The role of overweight in the long-term outcome of JIA is an issue that still needs to be addressed.

References:
Background: Vaccine-preventable diseases are again emerging in our population after anti-vaccine campaign has started. In autoinflammatory diseases (AID), vaccine triggered-disease is a well known phenomenon for Hyper-IgD/Mevalonate-Kinase Deficiency (MKD). In CAPS, severe flares have been experienced following pneumococcus vaccine, while PFAPA patients did not achieve sufficient and protective levels of antibodies. This evidence has raised doubts in physicians and families about the safety of vaccines.

Objectives: To evaluate, in a cohort of Italian AID, the vaccination coverage of the Italian Vaccination Schedule and the prevalence of adverse reactions and disease flares induced by vaccinations.

Methods: An anamnestic questionnaire was applied to AID patients referring to the AID Unit of the Istituto Giannina Gaslini from August 2017 to August 2018. Acquired data were revised for quality of information. Data about disease triggers in AID were obtained from the EUROFEVER registry for statistical reference.

Results: Triggers in AID Eurofever Registry: In August 2018 a total of 3783 patients were enrolled in the EUROFEVER registry (1908 female, 50.43%). The mean age of symptoms at disease onset was 7.04 +/- 9.48 SD yrs, (minimal 0 - maximum 75.92 yrs). The distribution among the periodic hereditary fevers was: 28.75% FMF (n=1081); 17.66% PFAPA (n=565); 9% Undiagnosed inflammatory disease (UND n=347); 7.85% CAPS (n=297); 7.16% TRAPS (n=271) and 5.39% MKD (n=204). Vaccines triggered the disease in 70% of the MKD, while PFAPA, TRAPS and UND had a rate of reactions of 20%. This was also found in 12.34% of CAPS, whereas FMF and inflammatory bone disorders had a rate of 6% and 3%, respectively. Excluding other causes of reactions, and isolating just vaccines as a cause, MKD had a higher percentage of reactions (7.14%), while PFAPA and UND had 1% and CAPS, TRAPS, FMF and inflammatory bone disorders had less than 1%

Triggers in IGG cohort: 150 questionnaires were distributed with 70% rate of response. Quality of data was 100% for coverage and adverse reactions. 105 patients were identified: PFAPA (n=26); CAPS (n=5); TRAPS (n=6); FMF (n=20); Inflammatory Bone Disorders (CRMO and PAPA, n=4) and UND (n=41). Rate of coverage was lower than 90% for Hib3 (83.11%), MMR/ MMRV (88.9%) and for Rota C (1.85%). For DTP3, Hep3, PCV3 and IPV the rate of coverage was higher than 90% for all vaccines. 11 moderate/severe reactions were observed as following: 5 after DTPA+IPV (1 PFAPA; 2 TRAPS, 1 MKD and 1 UND); 1 after Hib (PFAPA); 1 after P10/13 (PFAPA); 4 after MPR (1 PFAPA, 1 TRAPS, 1 MKD and 1 UND). The general rate of severe reactions/shots was 6.36 for 1000 shots and no severe infection, death, persistent or significant disability or life-threatening condition was observed. Just one MKD patient had a severe disease flare requiring hospitalization following pneumococcal vaccine.

Conclusion: Data show that in AID patients vaccines may more frequently trigger disease flare requiring hospitalization following pneumococcal vaccine.

REFERENCES:

Disclosure of Interests: Sara Signa: None declared, Caterina Matucci Cerinic: None declared, Enrica Toniolo: None declared, Marta Bustafina: None declared, Matteo D’ Alessandro: None declared, Stefano Volpi: None declared, Roberta Caorsi: None declared, Leonardo Oliveiro Mendonca: None declared, Marco Gattorno: Grant/research support from: MG has received unrestricted grants from Sobi and Novartis.